News
Market and company headlines
SOLVAll
Loading
11:00Oct 231 Story
09:00Oct 221 Story
06:00Oct 211 Story
12:00-17:00Oct 192 Stories
Solventum Announces FDA 510(k) Clearance for Combined Use of Restrata™ Matrix and Solventum™ V.A.C.® Therapy*
Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber Matrix and Solventum™ V.A.C.® Therapy*. Following Solventum's acquisition of Acera Surgical in December 2025, this regulatory milestone brings two advanced technologies together into one path to support active wound healing.
Solventum Receives FDA Clearance For Combined Use Of Restrata Synthetic Electrospun Fiber Matrix, Solventum V.A.C. Therapy
Solventum (NYSE: SOLV), a leader in advanced wound healing, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the combined use of Restrata™ Synthetic Electrospun Fiber
16:00Oct 151 Story
11:00Oct 81 Story
04:00Oct 21 Story
06:00Sep 291 Story
06:00Sep 251 Story
06:00Sep 241 Story
08:00Sep 231 Story
03:00Sep 181 Story
02:00Sep 171 Story
12:00Sep 161 Story
02:00Sep 141 Story
08:00Sep 91 Story
09:00Aug 201 Story
07:00Aug 141 Story
21:00Aug 121 Story
05:00Aug 111 Story
03:00-05:00Aug 92 Stories
Solventum (SOLV) Stock Fair Value Rises After Q2 And HIS Separation Plans
Solventum’s analyst fair value estimate has been revised from US$82.15 to US$93.15, a shift of about 13% in the updated framework. This adjustment aligns with recent analyst commentary that points to Q2 results, the planned Health Information Systems separation, and views on the company’s MedTech focus as reasons to revisit price targets. Read on to see how these factors shape the evolving Solventum narrative and what to watch as new data comes in. Analyst Price Targets don't always capture...
Solventum Q2 Earnings Call Highlights
Solventum (NYSE:SOLV) reported second-quarter results that exceeded its internal expectations, supported by broad-based segment performance, planned order activity ahead of an ERP cutover and a tariff refund benefit. The company also announced plans to separate its Health Information Systems, or HIS
10:00-14:00Aug 62 Stories
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
UBS Maintains Buy on Solventum, Raises Price Target to $101
UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $95 to $101.